These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26179454)

  • 21. dulaglutide (Trulicity°) weekly in type 2 diabetes: Cardiovascular reactions should be better documented.
    Prescrire Int; 2016 Oct; 25(175):236-237. PubMed ID: 30645827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
    Weinstock RS; Guerci B; Umpierrez G; Nauck MA; Skrivanek Z; Milicevic Z
    Diabetes Obes Metab; 2015 Sep; 17(9):849-58. PubMed ID: 25912221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.
    Fahrbach JL; Fu H; Shurzinske L; Skrivanek Z; Martin S
    Int J Clin Pract; 2016 Mar; 70(3):218-21. PubMed ID: 26916354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
    Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
    Umpierrez G; Tofé Povedano S; Pérez Manghi F; Shurzinske L; Pechtner V
    Diabetes Care; 2014 Aug; 37(8):2168-76. PubMed ID: 24842985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.
    de la Peña A; Loghin C; Cui X; Zhang X; Kapitza C; Kelly RP
    Diabetes Obes Metab; 2017 Apr; 19(4):517-523. PubMed ID: 27976833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
    Frias JP; Wynne AG; Matyjaszek-Matuszek B; Bartaskova D; Cox DA; Woodward B; Li YG; Tham LS; Milicevic Z
    Diabetes Obes Metab; 2019 Sep; 21(9):2048-2057. PubMed ID: 31050143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c.
    Romera I; Conget I; Vazquez LA; Gentilella R; Lebrec J; Jódar E; Reviriego J
    J Diabetes Complications; 2020 Jul; 34(7):107575. PubMed ID: 32220551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
    Dungan KM; Raz I; Skrivanek Z; Sealls W; Fahrbach JL
    Diabetes Obes Metab; 2016 Jan; 18(1):49-55. PubMed ID: 26362460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
    Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
    Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
    Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF
    Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
    Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
    Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dulaglutide: A Review in Type 2 Diabetes.
    Burness CB; Scott LJ
    BioDrugs; 2015 Dec; 29(6):407-18. PubMed ID: 26423061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
    Emoto M; Oura T; Matsui A; Kazama H; Iwamoto N
    Endocr J; 2017 Feb; 64(2):191-206. PubMed ID: 27853058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
    Pozzilli P; Leslie RD; Peters AL; Buzzetti R; Shankar SS; Milicevic Z; Pavo I; Lebrec J; Martin S; Schloot NC
    Diabetes Obes Metab; 2018 Jun; 20(6):1490-1498. PubMed ID: 29377522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
    Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
    J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.
    Wang J; Li HQ; Xu XH; Kong XC; Sun R; Jing T; Ye L; Su XF; Ma JH
    Biomed Res Int; 2019; 2019():2682657. PubMed ID: 31950036
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
    Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
    Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
    Yajima T; Yajima K; Hayashi M; Takahashi H; Yasuda K
    J Diabetes Complications; 2018 Mar; 32(3):310-315. PubMed ID: 29366733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.